BTAIQ — BioXcel Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1720893 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 182,000 | 160,000 | -10,193,000 | -14,713,000 | 28,799,000 | 12,841,000 | 144,259,000 |
| Mar 2026 | 206,000 | -77,000 | -10,223,000 | -12,691,000 | 34,025,000 | 17,180,000 | 139,568,000 |
| Dec 2025 | 256,000 | 224,000 | -10,282,000 | -12,545,000 | 44,916,000 | 28,415,000 | 140,379,000 |
| Sep 2025 | 98,000 | 87,000 | -14,034,000 | -30,911,000 | 44,792,000 | 36,176,000 | 133,711,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-50,904,000
Investing CF
$0
Financing CF
$46,130,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.66
As of
2026-09-20
Balance + Analyst (yfinance extras)
Retained Earnings
$-747,498,000
Inventory
$483,000
Receivables
$82,000
ST Investments
—
EBIT TTM
$-53,636,000
Pretax Income TTM
$-70,860,000
Interest Exp TTM
$17,224,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 642,000 | -50,267,000 | -69,897,000 | 44,916,000 | 140,379,000 | -95,463,000 | -57,615,000 |
| Dec 2024 | 2,266,000 | -64,804,000 | -59,599,000 | 38,338,000 | 131,439,000 | -93,101,000 | -72,027,000 |
| Dec 2023 | 1,380,000 | -167,619,000 | -179,053,000 | 73,702,000 | 130,210,000 | -56,508,000 | -155,006,000 |
| Dec 2022 | 375,000 | -159,645,000 | -165,757,000 | 205,853,000 | 129,078,000 | 76,775,000 | -135,341,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
Recent Insider Activity
No insider activity indexed for this ticker.